You are here: Home » PTI Stories » National » News
Business Standard

Cipla, Unitaid ink pact to cut price of HIV drug

Press Trust of India  |  Geneva/New Delhi 

Drug and Switzerland-based have inked a pact under which the Indian drug would reduce price of a combination therapy which prevents in people living with

Under the agreement, will reduce the ceiling price of the (Q-TIB) by more than 30 per cent from USD 3 to USD 1.99 per person, per month, for all public-sector procurers in low- and middle-income countries, said in a statement.

The agreement would lead to reduction in price of Q-TIB, as governments and international funding bodies procure large quantities for their treatment programmes.

"Unitaid-funded projects are putting more people on improved treatment, but we continue to see high rates of opportunistic infections," said.

By preventing these deadly infections, more people living with HIV will lead healthier lives, he added.

The HIV virus can weaken the immune system, increasing the risk of by bacteria and viruses. Q-TIB has been in the market since 2017 but its high price has put it out of reach of various countries' budgets.

The combination therapy is a once-daily pill that protects in three ways against TB, the leading cause of death among people with HIV, and against other life-threatening bacterial, and protozoan

According to WHO, in 2016, about one million people died of AIDS-related illnesses. Of those, most died from TB, bacterial and fungal

Unitaid invests in new ways to prevent, diagnose and treat HIV/AIDS, hepatitis C, and

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, June 08 2018. 15:55 IST